Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions worldwide.
NAFLD and type 2 diabetes mellitus (T2DM) are known to frequently coexist and act …

Background Researchers have suggested that omega‐3 polyunsaturated fatty acids from
oily fish (long‐chain omega‐3 (LCn3), including eicosapentaenoic acid (EPA) and …

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver diseases in high-
income countries and the burden of NAFLD is increasing at an alarming rate. The risk of …

Abstract Aims/hypothesis The EFFECT-II study aimed to investigate the effects of
dapagliflozin and omega-3 (n-3) carboxylic acids (OM-3CA), individually or combined, on …

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …

Background and Aims The development and progression of hepatocellular carcinoma
(HCC) is dependent on its local microenvironment. Tumor‐associated macrophages (TAMs) …

The prevalence of nonalcoholic steatohepatitis (NASH) is increasing worldwide, yet there
are no effective treatments. A decade has passed since the initial lipidomics analyses of liver …

Non-alcoholic fatty liver disease (NAFLD) is caused by an accumulation of fat in the liver; the
condition can progress over time to increase the risk of developing cirrhosis, end-stage liver …

Background Evidence on the health effects of total polyunsaturated fatty acids (PUFA) is
equivocal. Fish oils are rich in omega‐3 PUFA and plant oils in omega‐6 PUFA. Evidence …

Fatty liver disease (FLD), including its more severe pathologies, namely steatohepatitis,
hepatocarcinoma, and cirrhosis, is the most common cause of chronic liver disease …